Calamos Advisors LLC Summit Therapeutics Inc. Transaction History
Calamos Advisors LLC
- $16.8 Billion
- Q4 2024
A detailed history of Calamos Advisors LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 23,821 shares of SMMT stock, worth $484,042. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,821
Previous 46,747
49.04%
Holding current value
$484,042
Previous $1.02 Million
58.46%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$496 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$237 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$160 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$133 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$114 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.09B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...